Seattle Genetics preps for busy fall

Dealmaking machine Seattle Genetics is expecting a busy fall, says Seeking Alpha. Between September and October, the drug developer will recieve results from up to three clinical trials, two of which cover the company's flagship drug SGN-35 (brentuximab vedotin). The drug, which has been fast-tracked by the FDA, is in Phase III testing for Hodgkin's lymphoma and anaplastic large cell lymphoma. A Phase I study is also under way that is testing whether SGN-35 can be used for...

Seattle Genetics scores $900M cancer pact with Genentech

Genentech has anted up $12 million to expand its development pact for Seattle Genetics' antibody-drug conjugate (ADC) technology. And the Seattle biotech will now be able to play for a pot of cash that could swell to $900 million in fees and milestones. Genentech has already shelled out $30 million to Seattle Genetics over the past eight years. Impressed by the technology's ability to match a tumor-targeting antibody with a cancer-killing toxin, Genentech now wants to expand its group of...